Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...